Immune landscape of pancreatic cancer development and drug resistance.
Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells.
Saved in:
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
[S.l.] :
Academic Press,
2024.
|
| Series: | Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy ;
v. 5 |
| Subjects: | |
| Online Access: | ScienceDirect |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Napabucasin for metastatic PDAC
- Atezolizumab and cabozantinib for metastatic PDAC
- Dendritic cell vaccine in PDAC
- Conclusion
- References
- Chapter 4: Targeting macrophages for pancreatic cancer therapy
- Introduction
- How do TAMs originate?
- Role of TAMs in PDAC inflammation
- Angiogenesis
- Metastasis
- Immunity escape
- Chemotherapy resistance
- TAMs polarization
- Colony-stimulating factors, cytokines, and other molecules
- Inflammation related to TLRs
- Metabolic factors
- Exosomes
- Therapeutic potential of TAMs
- Redirection of TAMs
- Decreasing the amount of TAMs in ECM
- Conclusions and future prospects
- Funding
- References
- Chapter 5: Targeting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
- Introduction
- Tumor microenvironment
- Cancer-associated fibroblasts
- Quiescent cancer-associated fibroblasts
- Activated cancer-associated fibroblasts
- PDAC-associated fibroblast populations and their paracrine signaling
- Therapeutic targets of cancer-associated fibroblasts
- Targeting approaches for cancer-associated fibroblasts
- Direct approach
- Targeting the surface markers
- Targeting the signaling pathways between CAFs and TME
- Modifying CAFs from ``activeþþ to ``quiescentþþ stage
- Targeting CAF-derived ECM proteins
- Indirect approaches
- CAF causing therapeutic resistance
- Conclusion
- References
- Chapter 6: Targeting short-lived immunosuppressive myeloid cells for PDAC therapy
- Introduction
- Immune response in tumor cells
- Overview of types of myeloid cells found in the tumor microenvironment
- Myeloid-derived suppressor cells
- Methods of immunosuppression by MDSCs
- Tumor-associated macrophages
- Dendritic cells
- Importance of targeting myeloid immunosuppression
- Different examples of short-lived myeloid immunosuppression in PDAC.
- Vaccines directed against the VEGF receptor
- Kinesin family member 20A protein
- Survivin
- Mesothelin
- Other common cancer vaccines
- Local ablation along with immunotherapy
- Irreversible electroporation with immunotherapy
- Stereotactic ablative body radiotherapy with immunotherapy
- Summary
- Funding
- References
- Chapter 10: Precision medicine for PDAC immunotherapy
- Introduction
- Overview of pancreatic ductal adenocarcinoma
- Defining precision medicine
- Call for targeted therapy in the treatment of PDAC
- Types of treatments of PDAC using precision medicine
- Precision medicine targets of chemotherapy
- Precision medicine targets of immunotherapy
- Targeting immune checkpoint inhibitors in tumors with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR)
- Chimeric antigen receptor (CAR) T-cell therapy
- Targeting inhibition of connective tissue growth factor (CTGF)
- Precision medicine combining both chemotherapy and immunotherapy
- Vaccine therapy
- Targeting CD40 in combination with chemotherapy
- Autophagy and hydroxychloroquine in combination with chemotherapy
- Conclusion
- References
- Chapter 11: Application of artificial intelligence and machine learning in pancreatic cancer immunotherapy
- Introduction
- Challenges in the field
- Pancreatic cancer
- Immunotherapy
- Applications of AI/ML in pancreatic cancer immunotherapy
- Early diagnosis
- Medical imaging
- Endoscopic ultrasound (EUS)
- Computed tomography (CT)
- Magnetic resonance imaging (MRI)
- Precision medicine and predictive modeling
- Immunotherapy
- Challenges and future perspectives
- References
- Chapter 12: Enigmatic role of T cells in pancreatic ductal adenocarcinoma: An introspective study
- Introduction
- Tumor microenvironment of PDAC
- Role of T-cells in the progression and pathogenesis of PDAC.
- T-cell phenotypes playing a crucial role in PDAC
- Mechanisms behind T-cell exhaustion in PDAC
- Status of T-cell-based immunotherapy in PDAC
- Conclusion
- References
- Chapter 13: Delivery strategies of immunotherapies in the treatment of pancreatic cancer
- Introduction
- Cancer immunotherapy
- Passive immunotherapy
- Monoclonal antibodies
- Cytokine therapies
- Adoptive cell transfer therapy
- Active immunotherapy
- Peptide vaccines
- Dendritic cells (DCs)
- Whole-cell vaccines
- Immune checkpoint inhibitors (ICIs)
- Oncolytic viruses
- Delivery strategies for immunotherapy
- Nanoparticles
- Extracellular vesicles
- Implantable scaffolds
- Injectable scaffolds
- Cell-based delivery systems
- Conclusion
- Acknowledgment
- References
- Chapter 14: Current clinical trials in pancreatic ductal adenocarcinoma immunotherapy
- Introduction
- PDAC current therapeutic options
- Common chemotherapy regimens
- PDAC radiation therapy
- Limitations: Limitations of current therapeutic options
- Gemcitabine resistance
- Immunotherapy in cancer
- Immune checkpoint inhibitors
- Application of immunotherapy for PDAC
- Clinical trials
- Conclusion
- References
- Chapter 15: Managing adverse effects of novel immunotherapy in pancreatic cancer
- Introduction
- Immunotherapy
- Immune-checkpoint inhibitors
- Side effects and management of immunotherapy
- Cutaneous irAEs
- GI irAEs
- Liver irAEs
- Pancreas irAEs
- Pulmonary irAEs
- Endocrine irAEs
- Neurological irAEs
- Cardiac irAEs
- Conclusions and future perspectives
- Authors contribution
- References
- Chapter 16: Cathepsin B: Structure-function, metastatic role, and prognostic value in pancreatic carcinoma
- Introduction
- Structure-functional properties of cathepsin B and its metastatic role in pancreatic carcinoma
- Structure of cathepsin B.